SAN FRANCISCO, June 1, 2010 — ThinkEquity LLC – A Panmure Gordon Company, a leading investment banking boutique focused on growth companies and their investors, is pleased to announce the completion of the initial public offering of stock for GenMark Diagnostics Inc. on June 1, 2010. The Company issued 4,600,000 shares of common stock at a price of $6.00 per share raising gross proceeds of approximately $27.6 million. ThinkEquity LLC acted as a Co-Manager in this transaction. GenMark Diagnostics Inc.’s common stock is now trading on the NASDAQ Global Market under the symbol “GNMK”. GenMark Diagnostics is an emerging, pure-play molecular diagnostics company focused on developing, manufacturing, and marketing devices that facilitate molecular testing predominantly in genetic testing, but expanding into infectious disease and oncology testing. GenMark's eSensor electrochemical detection technology provides cutting-edge, cost-effectiveness and tools that enable a broader range of laboratories to offer molecular diagnostic services for improved patient care. The securities describe above were offered by GenMark Dianostics Inc. pursuant to a S1 registration statement previously filed with and declared effective by the Securities and Exchange Commission on May 28, 2010. The final prospectus is available at the SEC’s website at, or by contacting ThinkEquity LLC at 600 Montgomery Street, 3rd Floor, San Francisco, CA 94111, Attn: Prospectus Department 415-249-2935. ThinkEquity Contact: Janet Faleski Managing Director T: 212.468.7083 E: